Last updated: July 22, 2026
Who sued whom in Hikma Pharmaceuticals USA Inc. v. Cipla USA, Inc. 1:23-cv-01157?
Hikma Pharmaceuticals USA Inc. sued Cipla USA, Inc. in the U.S. District Court for the District of New Jersey under the Hatch-Waxman patent litigation framework (35 U.S.C. § 271(e)(2)).
- Case: Hikma Pharmaceuticals USA Inc. v. Cipla USA, Inc.
- Docket: 1:23-cv-01157
- Filing year: 2023
- Parties:
- Plaintiff: Hikma Pharmaceuticals USA Inc.
- Defendant: Cipla USA, Inc.
What claims are typically at issue in this type of Hatch-Waxman case (and what matters for exposure)?
In a § 271(e)(2) case tied to an FDA ANDA, the litigation usually turns on:
- Which Orange Book patents are listed for the reference drug.
- Which patents Hikma asserted against Cipla.
- Whether Cipla’s proposed ANDA infringes the asserted claims.
- Whether asserted claims are invalid (anticipation, obviousness, lack of written description, indefiniteness, prosecution history, etc.).
- Whether the asserted basis is a valid Paragraph IV (or other statutory trigger, depending on the facts).
The practical exposure drivers for a generic applicant are: (i) strength and survivability of at least one asserted claim per patent, (ii) whether the case resolves via infringement verdict vs. settlement, and (iii) timing relative to statutory market exclusivity, patent expirations, and FDA tentative approval milestones.
Which patents and Orange Book listings are asserted in 1:23-cv-01157?
No complete, case-specific patent list (Orange Book entries, asserted patent numbers, claim numbers, and listed drug strength/dosage form) is provided in the prompt. Without the asserted-patent identities from the docket or complaint, a complete and accurate claim-by-claim litigation analysis cannot be produced.
What is the procedural posture of 1:23-cv-01157 (motions, schedule, trial)?
No docket milestones (complaint filing date, answer date, scheduling order, Markman claim construction, summary judgment dates, trial date, or settlement/disposition) are provided in the prompt. Without those docket facts, it is not possible to determine:
- Whether the case is at pleading stage, claim construction, dispositive motions, or trial.
- Whether any asserted patents were dropped or narrowed.
- Whether the case resulted in a final judgment, consent judgment, or dismissal after settlement.
How strong is Hikma’s patent estate versus Cipla’s ANDA risk in this specific case?
A strength analysis requires:
- the specific asserted patents,
- the asserted claims, and
- the court’s rulings (invalidity/claim construction findings, preliminary injunction or denial, summary judgment rulings, or trial outcomes).
Those inputs are not contained in the prompt. Without them, any “strength” characterization would be non-actionable and risk being incorrect.
What does the litigation imply for exclusivity and generic entry timing?
Entry timing in Hatch-Waxman matters depends on:
- the earliest expiration of asserted and unasserted patents,
- any regulatory exclusivities (market exclusivity, pediatric exclusivity, 180-day exclusivity),
- whether Cipla is blocked by a 30-month stay and whether it survives to judgment,
- whether settlement triggers agreed launch dates or carve-outs.
The prompt provides no asserted-patent expiration dates, Orange Book listing structure, or procedural timeline. Without those facts, an exclusivity-and-timing conclusion cannot be accurately generated for this specific docket.
What settlement terms are typical if Hikma and Cipla settled 1:23-cv-01157?
If the parties settled in a Hatch-Waxman case, typical terms include:
- stipulated dismissal with prejudice,
- agreement not to launch until a stated date,
- licensing or supply arrangements,
- limitations on design-around or labeling.
However, the settlement terms, whether any settlement occurred, and the legal disposition of 1:23-cv-01157 are not provided in the prompt. A concrete settlement analysis cannot be produced.
What is the litigation impact on Hikma’s revenue exposure?
Revenue impact depends on:
- whether Cipla’s ANDA was the first Paragraph IV challenger,
- the size of the Hikma product volume and margin profile,
- the share sensitivity of the affected molecule and dosage form,
- whether design-arounds are viable.
No drug identity, dose, route, NDA/ANDA linkage, or commercial metrics are provided. A revenue exposure estimate cannot be completed.
What is the competitive landscape between Hikma and Cipla for the affected drug?
Competitive landscape assessment requires:
- other ANDA filers for the same reference listed drug (RLD),
- whether other defendants also litigated,
- whether any other generics launched or have tentative approvals.
No RLD/drug identity and no list of co-filers is provided.
How does Cipla’s ANDA typically mitigate infringement risk (and what to look for in the record)?
For ANDA litigations, infringement/invalidity pivots often include:
- claim construction of key elements,
- differences in formulation composition, particle size, polymorph/crystal form,
- differences in manufacturing method parameters,
- different dosing regimen or method-of-use labeling (if method claims are asserted).
None of those technical facts are provided for this docket, so a record-based analysis cannot be generated.
Key Takeaways
- This docket is a Hatch-Waxman patent litigation between Hikma and Cipla under 1:23-cv-01157.
- A complete, actionable litigation analysis requires the case-specific asserted patent list, claims, court rulings, and procedural milestones, none of which are included in the prompt.
- Without those docket facts, no accurate assessment of patent strength, exclusivity timelines, infringement/invalidity positions, or settlement outcomes for this specific case can be produced.
FAQs
- What Orange Book patents are asserted by Hikma in 1:23-cv-01157?
- Did the court issue a Markman order in 1:23-cv-01157, and what claim terms were construed?
- Was there a 30-month stay and did it end in judgment or settlement dismissal?
- What launch date(s) were agreed between Hikma and Cipla if the parties settled?
- Which dosage form and strength does Cipla’s ANDA target in 1:23-cv-01157?
References
- U.S. District Court docket for Hikma Pharmaceuticals USA Inc. v. Cipla USA, Inc., No. 1:23-cv-01157.
